工程化益生菌用于肿瘤靶向联合化学免疫治疗
Engineered probiotics for tumor-targeted combination chemoimmunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Targeting a disintegrin and metalloprotease (ADAM) 17-CD122 axis enhances CD8(+) T cell effector differentiation and anti-tumor immunity.
Targeting a disintegrin and metalloprotease (ADAM) 17-CD122 axis enhances CD8(+) T cell effector differentiation and anti-tumor immunity.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CD8阳性T细胞免疫反应受多层网络调控,但其翻译后调节仍知之甚少。跨膜蛋白胞外结构域脱落可通过蛋白水解调节受体表达和信号转导。本研究靶向脱落酶ADAM17,揭示了CD8阳性T细胞中由胞外结构域脱落介导的翻译后调控机制。转录组和蛋白组分析显示该机制参与CD8阳性T细胞调控。T细胞特异性敲除ADAM17显著促进效应CD8阳性T细胞分化,并增强其清除病原体和肿瘤的细胞毒作用。机制上,ADAM17切割膜蛋白CD122;抑制ADAM17可提高小鼠和人CD8阳性T细胞的CD122表达,增强对IL-2和IL-15的反应。抑制ADAM17还可提高实体瘤CAR-T 疗效。结果揭示重要翻译后调控机制,并提示靶向ADAM17可成为增强抗肿瘤免疫的潜在策略。
CD8 + T cell immune responses are regulated by multi-layer networks, while the post-translational regulation remains largely unknown. Transmembrane ectodomain shedding is an important post-translational process orchestrating receptor expression and signal transduction through proteolytic cleavage of membrane proteins.
Here, by targeting the sheddase A Disintegrin and Metalloprotease (ADAM)17, we defined a post-translational regulatory mechanism mediated by the ectodomain shedding in CD8 + T cells. Transcriptomic and proteomic analysis revealed the involvement of post-translational regulation in CD8 + T cells. T cell-specific deletion of ADAM17 led to a dramatic increase in effector CD8 + T cell differentiation and enhanced cytolytic effects to eliminate pathogens and tumors.
Mechanistically, ADAM17 regulated CD8 + T cells through cleavage of membrane CD122. ADAM17 inhibition led to elevated CD122 expression and enhanced response to IL-2 and IL-15 stimulation in both mouse and human CD8 + T cells. Intriguingly, inhibition of ADAM17 in CD8 + T cells improved the efficacy of chimeric antigen receptor (CAR) T cells in solid tumors.
Our findings reveal a critical post-translational regulation in CD8 + T cells, providing a potential therapeutic strategy of targeting ADAM17 for effective anti-tumor immunity.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。